126 related articles for article (PubMed ID: 23806981)
21. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
22. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
23. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
Troiani T; Zappavigna S; Martinelli E; Addeo SR; Stiuso P; Ciardiello F; Caraglia M
Expert Opin Biol Ther; 2013 Feb; 13(2):241-55. PubMed ID: 23281932
[TBL] [Abstract][Full Text] [Related]
24. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
[TBL] [Abstract][Full Text] [Related]
25. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
[TBL] [Abstract][Full Text] [Related]
26. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
Nakata A; Gotoh N
Expert Opin Ther Targets; 2012 Aug; 16(8):771-81. PubMed ID: 22762482
[TBL] [Abstract][Full Text] [Related]
27. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
28. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
Efferth T
Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
[TBL] [Abstract][Full Text] [Related]
29. MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells.
Boccaccio C; Luraghi P; Comoglio PM
Cancer Res; 2014 Jul; 74(14):3647-51. PubMed ID: 24986519
[TBL] [Abstract][Full Text] [Related]
30. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
Takegawa N; Yonesaka K
Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
[TBL] [Abstract][Full Text] [Related]
31. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Matos I; Elez E; Capdevila J; Tabernero J
Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
[TBL] [Abstract][Full Text] [Related]
32. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer.
Rihawi K; Giampieri R; Scartozzi M; Pusceddu V; Bonotto M; Fasola G; Cascinu S; Aprile G
Expert Opin Investig Drugs; 2015; 24(9):1185-98. PubMed ID: 26044119
[TBL] [Abstract][Full Text] [Related]
33. Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity?
Tejpar S; Piessevaux H
Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():2-10. PubMed ID: 24512508
[TBL] [Abstract][Full Text] [Related]
34. The role of the PI3K pathway in colorectal cancer.
Papadatos-Pastos D; Rabbie R; Ross P; Sarker D
Crit Rev Oncol Hematol; 2015 Apr; 94(1):18-30. PubMed ID: 25591826
[TBL] [Abstract][Full Text] [Related]
35. EGFR status is not a reliable biomarker to select patients suitable for cetuximab-based therapy.
Kim TW
Clin Colorectal Cancer; 2014 Mar; 13(1):3-4. PubMed ID: 24373734
[No Abstract] [Full Text] [Related]
36. Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer.
Ulivi P; Marisi G; Passardi A
Oncotarget; 2016 Jul; 7(29):46678-46691. PubMed ID: 27081084
[TBL] [Abstract][Full Text] [Related]
37. Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer.
Manzoni M; Comolli G; Torchio M; Mazzini G; Danova M
Clin Colorectal Cancer; 2015 Mar; 14(1):11-7. PubMed ID: 25591800
[TBL] [Abstract][Full Text] [Related]
38. Targeting FGF receptors in colorectal cancer: from bench side to bed side.
Abdel-Rahman O
Future Oncol; 2015; 11(9):1373-9. PubMed ID: 25952783
[TBL] [Abstract][Full Text] [Related]
39. Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer.
Garajová I; Ferracin M; Porcellini E; Palloni A; Abbati F; Biasco G; Brandi G
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714940
[TBL] [Abstract][Full Text] [Related]
40. Unraveling the Complexities of Treating Metastatic Colorectal Cancer With Angiogenesis Inhibitors.
Overstreet K; Van Cutsem E; Johnson M
Clin Colorectal Cancer; 2015 Sep; 14(3):131-2. PubMed ID: 26089238
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
